| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.17 | 3e-06 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.17 | 3e-06 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.19 | 5e-06 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.19 | 1e-05 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-05 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | -0.15 | 1e-05 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.15 | 1e-05 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.17 | 2e-05 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-05 |